A statutory ceiling, not the market, decided what Medicare’s Part D base beneficiary premium would be in 2027: six percent above the prior year’s amount. That formula, written into the Inflation Reduction Act and running through 2029, capped the 2027 benchmark at $41.33 even as the national average monthly bid plans submitted for basic drug coverage jumped to $296.05, a bid increase several times steeper than the premium was allowed to rise. The Centers for Medicare & Medicaid Services published both figures on July 28, 2026, the fourth year running that the ceiling has done the real work of holding the benchmark down.
The 6 Percent Ceiling Congress Wrote Into the IRA
The cap traces to a single line in the Inflation Reduction Act of 2022, the same law that created Medicare’s $2,000 out-of-pocket drug spending cap and the government’s drug price negotiation program. Starting with the 2024 plan year and running through 2029, the law does not let the Part D base beneficiary premium, the national benchmark figure CMS calculates each summer, rise by more than 6 percent over the prior year’s amount. The 2027 base beneficiary premium of $41.33 reflects that statutory limit, not an independent market calculation.
The arithmetic shows exactly how tight that ceiling is. The 2026 base beneficiary premium was $38.99; six percent above that figure is $41.3294, which CMS’s July 28 fact sheet rounds to $41.33 for 2027, the maximum the statute allows and the exact number CMS published. Over the same year, the national average monthly bid amount, the enrollment-weighted average of what Part D plan sponsors actually bid to cover basic drug benefits, jumped from $239.27 to $296.05, a rise of roughly 23.7 percent. Bidding costs for basic coverage grew about four times faster than the number beneficiaries see was allowed to move.
Part of that bid jump lines up with a second, unrelated CMS decision made the same day. The agency is ending the Part D Premium Stabilization Demonstration after 2026, a separate voluntary program that had been giving standalone prescription drug plans extra subsidies since 2025 specifically to blunt premium swings while insurers adjusted to the law’s benefit redesign. According to the Academy of Managed Care Pharmacy’s summary of the announcement, that demonstration worked by lowering the base beneficiary premium used in individual plan calculations and by limiting year-over-year premium increases directly, a second layer of protection that disappears for 2027 even as the statutory 6 percent cap stays fully in place.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
What the Cap Has Already Overridden Twice
The 2027 gap between bid growth and premium growth is not the first time the cap has done heavy lifting. For 2024, the first year the provision applied, CMS set the base beneficiary premium at $34.70, six percent above the 2023 amount of $32.74. Analysis from KFF, the health policy research organization, calculated that without the cap, the 2024 base premium would have landed at $39.35, a 20 percent increase driven by higher plan bids for the newly redesigned benefit.
The following year showed an even wider gap. CMS set the 2025 base beneficiary premium at $36.78, again exactly six percent above the prior year’s $34.70. KFF’s calculation of the uncapped alternative put the 2025 figure at $55.98, a 42 percent jump, more than seven times the growth rate beneficiaries actually saw. In both years, the cap did not just round off the numbers; it cut the increase to less than a third of what CMS’s own bid data implied.
CMS has not published its own uncapped counterfactual for 2027, so no verified dollar figure exists for what the base premium would have been without the statute. But the underlying pattern repeated: a bid increase in the low-to-mid twenty percent range against a premium capped at 6 percent is the same relationship that produced the $39.35 and $55.98 counterfactuals in the cap’s first two years. The consistency across three separate CMS bid cycles is what makes the mechanism, not the headline number, the real story of the 2027 announcement.
Why $41.33 Is Not What Any Enrollee Actually Pays
The base beneficiary premium is a calculation input, not a bill. Under the statutory formula, an individual Part D plan’s premium equals the base beneficiary premium plus the difference between that specific plan’s own bid and the national average monthly bid. A standalone drug plan that bid above the $296.05 national average charges its enrollees more than $41.33 a month, while a plan that bid below the average charges less, and many Medicare Advantage drug plans use rebate dollars to reduce their Part D premium to zero. CMS will not release the actual lineup of 2027 plan premiums until September.
Because the capped premium collects less from enrollees than the full bid amount would otherwise require, the shortfall has to be paid from somewhere else, and that somewhere is the federal government. CMS’s payment methodology for the redesigned benefit ties higher plan bids to substantially larger upfront direct subsidy payments made to plan sponsors, the mechanism that lets the government’s contribution rise in step with total program costs even while the beneficiary-facing benchmark is held to 6 percent. Taxpayers, not enrollees, absorb the gap between what the 6 percent cap collects and what plan bidding actually costs.
The gap matters most in 2027 because two protections are unwinding at once. The statutory 6 percent cap on the base beneficiary premium continues on schedule through 2029, so the benchmark number will keep climbing at a predictable, government-absorbed pace. But the separate Premium Stabilization Demonstration, which had been softening what individual standalone plans could charge on top of that benchmark, ends after this year. With bid costs up nearly 24 percent and that extra cushion gone, the plan-level premiums CMS discloses in September, not the $41.33 headline figure, will show whether 2027 enrollees feel the increase the capped number was built to hide.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
